GLP-1 and Testosterone for Men: Should You Test Before Starting TRT?

Yes. The American Urological Association (AUA) guideline says obese men are almost five times more likely to have low testosterone than men who are not obese, and that men with a BMI of 30 or more, or a waist over 40 inches, should have their testosterone checked (AUA Testosterone Deficiency Guideline, checked Oct 2026). In the European Male Ageing Study of 3,200 men aged 40 to 79, men with a BMI of 30 or more had lower total and free testosterone than men with a BMI under 25 (Wu et al., JCEM 2008, checked Oct 2026).

A link is not proof that weight is the cause for any one man; other conditions and medicines lower testosterone too, which is part of why a proper diagnosis matters.

Losing weight tends to raise it, and the more weight lost, the bigger the rise. A meta-analysis of 24 studies found total testosterone rose after both low-calorie diets and bariatric surgery, more after surgery, and that "the degree of body weight loss is the best determinant" of the rise (Corona et al., Eur J Endocrinol 2013, checked Oct 2026). The AUA guideline quotes the AACE view that meaningful improvements usually need a loss of 5–10% of body weight.

The GLP-1 evidence is small. In a 16-week randomized trial of 30 obese men with low testosterone, liraglutide raised total testosterone by 2.6 nmol/L on average (testosterone gel: 5.9), with 7.9 kg of weight loss against 0.9 kg on the gel (Jensterle et al., Endocr Connect 2019). In a 24-week trial of 25 men with type 2 diabetes, semaglutide and testosterone injections both raised total testosterone, but sperm counts fell only in the testosterone group (Diabetes Obes Metab 2025). A 2025 meta-analysis pooled just 4 studies (219 men) and noted the effect "is not yet covered by clinical guidelines" (BMC Urology 2025). We found no large Wegovy or Zepbound trial that reported testosterone in men. All checked Oct 2026.

With symptoms and repeat blood tests, not one number. The Endocrine Society recommends diagnosing low testosterone only in men with symptoms and signs of deficiency and "unequivocally and consistently low" levels: a fasting, early-morning total testosterone test with an accurate assay, confirmed by repeating it on another morning (Endocrine Society guideline, Bhasin et al. 2018, checked Oct 2026). The AUA uses a total testosterone below 300 ng/dL as a reasonable cut-off, measured twice on separate early mornings; it does not insist on fasting.

Symptoms the AUA guideline discusses include low sex drive, erectile dysfunction (including fewer morning erections), fatigue, loss of muscle, more belly fat and low mood. It also notes that stress, chronic fatigue or depression can cause the same symptoms, which is why the blood tests come first. Ask for the test early in the morning, and ask whether to repeat it after a few months of weight loss.

• Lose weight first and retest. If your level is borderline and you are starting a GLP-1, retesting after the weight comes down shows whether the low reading was tied to weight. Talk to your prescriber about timing.
• Testosterone therapy (TRT). Gels, injections and other forms, by prescription. The AUA guideline says patients should be told TRT may improve erectile function, low sex drive, anemia, bone density, lean mass and depressive symptoms, and that evidence is inconclusive for energy, fatigue and quality of life. It recommends commercially made testosterone over compounded when possible.
• Enclomiphene and clomiphene, offered by some clinics. There is no FDA-approved enclomiphene product. An FDA advisory committee voted in 2022 against FDA's proposal to keep it off the list of substances pharmacies may compound, and FDA's own list (updated May 2026) still shows it "under evaluation", so some compounding pharmacies make it while FDA decides (FDA, checked Oct 2026). Clomiphene (Clomid) is FDA-approved only for ovulation problems in women; its label says there are no adequate studies showing it works for male infertility, so use in men is off-label. The AUA lists this drug class among options for men with low testosterone who want to keep their fertility.

For now, yes, under temporary federal rules that run through December 31, 2026. Testosterone is a Schedule III controlled substance (21 CFR 1308.13 and DEA's controlled substance list, checked Oct 2026). DEA and HHS have extended the pandemic-era telemedicine flexibilities for controlled substances four times. The current extension, in effect from January 1 through December 31, 2026, lets a DEA-registered practitioner prescribe Schedule II–V drugs by telemedicine without a prior in-person exam, using a real-time two-way audio-video connection and meeting the other conditions in the rule (21 CFR 1307.41, checked Oct 2026).

A permanent "special registration" for telemedicine was proposed in January 2025 and is not final. What happens after December 31, 2026 depends on DEA's next rule, so check before relying on an online-only prescription for the long term.

• Guidelines: AUA, Evaluation and Management of Testosterone Deficiency (Mulhall et al., 2018; validity confirmed 2024); Endocrine Society, Testosterone Therapy in Men With Hypogonadism (Bhasin et al., JCEM 2018). Both checked Oct 2026.
• Obesity and testosterone: European Male Ageing Study, Wu et al., JCEM 2008; weight loss meta-analysis, Corona et al., Eur J Endocrinol 2013.
• GLP-1 studies: liraglutide, Jensterle et al., Endocr Connect 2019; semaglutide, Diabetes Obes Metab 2025; meta-analysis, BMC Urology 2025.
• Enclomiphene and clomiphene: FDA Pharmacy Compounding Advisory Committee, minutes and transcript (June 2022); FDA 503A bulk drug substances nominations list (updated May 2026) and interim policy (January 2025); Clomid label on DailyMed. Checked Oct 2026.
• Controlled substance and telemedicine rules: 21 CFR 1308.13 (Schedule III), DEA controlled substances list, 21 CFR 1307.41 (Fourth Temporary Extension, published in the Federal Register on Dec 31, 2025). Checked Oct 2026.